Professor, Medicine, Vanderbilt University School of Medicine
Pulmonology
Dr. Ivan Robbins, MD
|
|
Give Review
Ivan Robbins works in the field of Pulmonology. He researched medicine at Case Western Reserve University School of Medicine. He received 1 awards: "Meaningful Use Stage 1 Certification". Dr. Ivan Robbins is also published. He has 71 publications published. The lastest publication: "A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension.' He is registered with Medicare.
Publications
- Valsalva Maneuver in Pulmonary Arterial Hypertension: Susceptibility to Syncope and Autonomic Dysfunction.
- Prognostic value of acute vasodilator response in Pulmonary arterial hypertension: Beyond the "classic" responders.
- Variability in hemodynamic evaluation of Pulmonary hypertension at large referral centers.
- Serum Endostatin is a Genetically Determined Predictor of Survival in Pulmonary Arterial Hypertension.
- ERG-APLNR Axis Controls Pulmonary Venule Endothelial Proliferation in Pulmonary Veno-Occlusive Disease.
- Impact of diabetes on survival and right ventricular compensation in Pulmonary arterial hypertension.
- Two formulations of epoprostenol sodium in the treatment of Pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in Pulmonary arterial hypertension),...
- Shorter survival in familial versus idiopathic Pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular function.
- Reproducibility of intracardiac and transPulmonary biomarkers in the evaluation of Pulmonary hypertension.
- Genome-wide association analysis identifies a susceptibility locus for Pulmonary arterial hypertension.
- Physical activity limitation as measured by accelerometry in Pulmonary arterial hypertension.
- T lymphocyte subset abnormalities in the blood and lung in Pulmonary arterial hypertension.
- A study of aspirin and clopidogrel in idiopathic Pulmonary arterial hypertension.
- Combination of bosentan with epoprostenol in Pulmonary arterial hypertension: BREATHE-2.
- Effects of the dual endothelin-receptor antagonist bosentan in patients with Pulmonary hypertension: a randomised placebo-controlled study.
- Continuous intravenous epoprostenol for Chronic thromboembolic pulmonary hypertension.
- Molecular and functional analysis identifies ALK-1 as the predominant cause of Pulmonary hypertension related to hereditary haemorrhagic telangiectasia.
- Venous and arterial changes in Pulmonary veno-occlusive disease, mitral stenosis and fibrosing mediastinitis.
- Angiotensin II mediates systemic rebound Hypertension after cessation of prostacyclin infusion in sheep.
- Pulmonary vasoreactivity in PPH.
- Pulmonary artery stenosis and fibrous mediastinitis.
- Iatrogenic paradoxical air embolism in Pulmonary hypertension.
- Continuous intravenous epoprostenol for Pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
- The 6-min walk test (6MW) as an efficacy endpoint in Pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect.
- An interesting electrolyte problem.
- A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases.
- Predictors of diastolic-to-wedge gradient in patients evaluated for Pulmonary hypertension.
- Miliary tuberculosis as a cause of acute Empyema.
- Advancing therapy for Pulmonary arterial hypertension: can animal models help?
- Acute effects of sildenafil in patients with primary Pulmonary hypertension receiving epoprostenol.
- Pathologic assessment of vasculopathies in Pulmonary hypertension.
- Oxidant stress but not thromboxane decreases with epoprostenol therapy.
- Gross BMPR2 gene rearrangements constitute a new cause for primary Pulmonary hypertension.
- Serotonin transporter polymorphisms in familial and idiopathic Pulmonary arterial hypertension.
- Outcome after cardioPulmonary resuscitation in patients with Pulmonary arterial hypertension.
- Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary Pulmonary hypertension.
- Outcome in 91 consecutive patients with Pulmonary arterial hypertension receiving epoprostenol.
- Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II.
- Efficacy and safety of treprostinil: an epoprostenol analog for primary Pulmonary hypertension.
- Beraprost therapy for Pulmonary arterial hypertension.
- Effects of the dual endothelin receptor antagonist bosentan in patients with Pulmonary arterial hypertension: a 1-year follow-up study.
- Sitaxsentan therapy for Pulmonary arterial hypertension.
- High frequency of BMPR2 exonic deletions/duplications in familial Pulmonary arterial hypertension.
- Temporal trends and drug exposures in Pulmonary hypertension: an American experience.
- Exercise training in Pulmonary hypertension: implications for the evaluation of drug trials.
- Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with Pulmonary arterial hypertension.
- Selective endothelin A receptor antagonism with sitaxsentan for Pulmonary arterial hypertension associated with connective tissue disease.
- Hysteroscopic sterilization in women with Pulmonary vascular disease.
- Sildenafil monotherapy in portoPulmonary hypertension can facilitate liver transplantation.
- Association of the metabolic syndrome with Pulmonary venous hypertension.
- A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic Pulmonary arterial hypertension.
- Incidence of pleural effusions in idiopathic and familial Pulmonary arterial hypertension patients.
- Updated clinical classification of Pulmonary hypertension.
- Diagnosis, assessment, and treatment of non-Pulmonary arterial hypertension Pulmonary hypertension.
- Congenital pulmonary artery stenoses masquerading as Chronic thromboembolic disease.
- Truncating and missense BMPR2 mutations differentially affect the severity of heritable Pulmonary arterial hypertension.
- Addition of inhaled treprostinil to oral therapy for Pulmonary arterial hypertension: a randomized controlled clinical trial.
- Safety of sapropterin dihydrochloride (6r-bh4) in patients with Pulmonary hypertension.
- Frequency of pleural effusions in patients with Pulmonary arterial hypertension associated with connective tissue diseases.
- Unrecognized glucose intolerance is common in Pulmonary arterial hypertension.
- Left atrial Hypertension after repeated catheter ablations for atrial fibrillation.
- End tidal CO(2) tension: Pulmonary arterial hypertension vs Pulmonary venous hypertension and response to treatment.
- Long-term effects of inhaled treprostinil in patients with Pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arte...
- Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression.
- A survey of diagnostic practices and the use of epoprostenol in patients with primary Pulmonary hypertension.
- Epoprostenol for treatment of Pulmonary hypertension in patients with systemic lupus erythematosus.
- Pulmonary veno-occlusive disease: a case series and new observations.
- Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary Pulmonary hypertension.
- Pulmonary vein stenosis after catheter ablation of atrial fibrillation.
- Percutaneous Pulmonary artery and vein stenting: a novel treatment for mediastinal fibrosis.
Schools
Case Western Reserve University School of Medicine
Metrohealth Med Center
Case West Res Metrohealth Med Center
Vanderbilt University and Med Center
Procedures Preformed
- Bronchoscopy
- Continuous Positive Airway Pressure (CPAP)
- Thoracentesis
- Ventilation Management
Conditions Treated
- Acidosis
- Alkalosis
- Asbestosis
- Asthma
- View All
Doctors Specialties
- Critical Care Medicine
- Pulmonology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
Vanderbilt University -
Case Western Reserve University - MetroHealth -
Case Western Reserve University School of Medicine
Hospital
-
Vanderbilt Hospital and Clinics
Drug Facts
| NPI NUMBER | 1083713424 | |
| NPPES Provider LastName | ROBBINS | |
| NPPES Provider FirstName | IVAN | |
| NPPES Provider ZIPCode | 372320001 | |
| NPPES Provider State | TN | |
| Specialty Description | Pulmonary Disease | |
| Total Claim Count | 1473.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083713424 |
| Last Name Of The Provider | ROBBINS |
| First Name Of The Provider | IVAN |
| View All |
Similar Doctors
|
|
Dr. Jon J. Tumen, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Karl P. Kuhn, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Charles J. Wray, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jack W. Coggeshall, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey G. Wright, MD |
|
|
Dr. Carla M. Sevin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason B. Martin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence W. Freund, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William E. Lawson, MD |
|
|
Dr. Richard Light, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Devon W. Paul, MD |